**Message from the Guest Editor**

Dear Colleagues,

I suggest reviewing the following topics:

- Checkpoint regulators and the combinations thereof. The first generation one-mAb-one-target paradigm struggles in the face of tumour heterogeneity and evolution. In contrast, the checkpoint regulator mAbs aim to reactivate the patient’s own cellular immune response in tumour microenvironment in an effort to eradicate tumour cells displaying any neoantigens, hence potentially benefiting a much wider range of patients.

- T cell engagers: Bispecific engineered antibody-based molecules aim to re-direct and trigger response of cytotoxic T cells of any specificity by cross-linking them to the tumour cells displaying a specific surface protein target or a MHC–peptide complex.

- CARs and TRUCKs: tumour-specific antibody fragments displayed on engineered cytotoxic T cell surface

- Bispecific antibodies for more nuanced tumour cell targeting where binding is limited only to cells expressing a combination of two different targets, not just one or the other. As a result, significantly reduced off-target bystander cell damage can be expected.

**Author Benefits**

**Open Access:** free for readers, with publishing fees paid by authors or their institutions.

**High visibility:** Indexed in the Emerging Sources Citation Index (ESCI - Web of Science), EMBASE (Elsevier) and other databases.

**Rapid publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 57 days after submission; acceptance to publication is undertaken in 12 days (median values for papers published in this journal in 2016).